FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

PEG-MGF

PEGylated Mechano Growth Factor

Growth Factors

PEG-MGF (PEGylated Mechano Growth Factor) is a modified version of the MGF splice variant of IGF-1 with polyethylene glycol chains attached to extend its biological half-life from minutes to several hours. This PEGylation converts MGF from a locally-acting autocrine factor into a systemically bioavailable peptide capable of reaching muscle tissue through the circulation. It is a research compound studied for enhanced muscle repair, recovery, and growth signaling with more practical dosing compared to unmodified MGF.

作用機序

PEGylated version of mechano growth factor with polyethylene glycol chains attached to extend half-life. Preserves satellite cell activation and muscle repair properties of MGF while allowing systemic rather than purely local administration.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 200-400mcg 2-3 times per week via intramuscular injection into target muscle groups. Can be rotated across muscle groups. Cycles of 4-8 weeks.

研究ノート

Clinical Research Status

PEG-MGF has not entered formal clinical trials and remains a research-grade compound without regulatory status. Its development represents a pharmacokinetic optimization of the naturally-occurring MGF splice variant to address the impractically short half-life of the native peptide. Academic interest focuses on whether systemic delivery of PEGylated MGF can replicate the local satellite cell activation observed with natural MGF expression after exercise.

Key Published Findings

Animal studies suggest PEGylated MGF administered systemically can reach muscle tissue and promote satellite cell activation, though at lower local concentrations than achieved through direct intramuscular injection of native MGF. The PEGylation extends circulating half-life from approximately 5-7 minutes to several hours, allowing subcutaneous administration with meaningful systemic exposure. Research indicates the PEG moiety does not significantly impair receptor binding of the E-domain peptide.

Safety Profile

No human safety data exists for PEG-MGF, and risk assessment relies entirely on extrapolation from in vitro and animal studies. PEGylated compounds carry general risks of PEG-associated immune responses (anti-PEG antibodies) with repeated dosing, potentially reducing efficacy over time. The systemic nature of PEG-MGF raises broader safety considerations than local MGF, as satellite cell activation in non-target tissues (including cardiac muscle) could potentially occur.

Comparison to Related Compounds

Compared to unmodified MGF, PEG-MGF offers practical subcutaneous dosing but loses the tissue-specific local action that characterizes natural MGF biology. Unlike IGF-1 LR3 which activates the full IGF-1 receptor signaling cascade, PEG-MGF theoretically targets the earlier satellite cell activation phase rather than direct protein synthesis stimulation. The PEGylation approach mirrors pharmaceutical strategies used for other peptides (PEG-filgrastim, PEG-interferon) to reduce dosing frequency.

Community Observations

Protocols typically use PEG-MGF at 200-400 mcg administered subcutaneously on training days, based on empirical use rather than pharmacokinetic optimization. Some researchers question whether the PEGylated form adequately replicates the natural autocrine signaling pattern or whether systemic delivery fundamentally changes the biological response. The compound is often used in combination with IGF-1 LR3, with PEG-MGF theorized to expand satellite cell populations that IGF-1 LR3 then drives toward differentiation and hypertrophy.

半減期

~Several days

再構成

Bacteriostatic water (BAC)

保存

乾燥粉末

Refrigerate 2-8C up to 18 months.

再溶解

Refrigerate 2-8C. Use within 14 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

PEGylated Mechano Growth Factor

よくある質問

PEG-MGFとは何ですか?

PEG-MGF (PEGylated Mechano Growth Factor) is a modified version of the MGF splice variant of IGF-1 with polyethylene glycol chains attached to extend its biological half-life from minutes to several hours. This PEGylation converts MGF from a locally-acting autocrine factor into a systemically bioavailable peptide capable of reaching muscle tissue through the circulation. It is a research compound studied for enhanced muscle repair, recovery, and growth signaling with more practical dosing compared to unmodified MGF.

PEG-MGFはどのように作用しますか?

PEGylated version of mechano growth factor with polyethylene glycol chains attached to extend half-life. Preserves satellite cell activation and muscle repair properties of MGF while allowing systemic rather than purely local administration.

PEG-MGFの米国での規制状況は?

Research chemical (not FDA-approved)

PEG-MGFの半減期は?

~Several days

PEG-MGFの別名は?

PEGylated Mechano Growth Factor

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む